See how top analysts and institutions rate NVDA — including buy, hold, and sell recommendations.
| Rating Source | Action | Rating | Target Price | Updated |
|---|---|---|---|---|
| HSBC Securities | Upgrade | Hold → Buy | $320 | 2025-10-15 |
| Cantor Fitzgerald | Reiterated | Overweight | $240 → $300 | 2025-10-09 |
| Citigroup | Reiterated | Buy | $200 → $210 | 2025-09-30 |
| KeyBanc Capital Markets | Reiterated | Overweight | $230 → $250 | 2025-09-30 |
| Barclays | Reiterated | Overweight | $200 → $240 | 2025-09-25 |
| Evercore ISI | Reiterated | Outperform | $214 → $225 | 2025-09-23 |
| DA Davidson | Upgrade | Neutral → Buy | $210 | 2025-09-11 |
| Citigroup | Reiterated | Buy | $210 → $200 | 2025-09-08 |
| The Benchmark Company | Reiterated | Buy | $190 → $220 | 2025-08-28 |
| BofA Securities | Reiterated | Buy | $220 → $235 | 2025-08-28 |
| Jefferies | Reiterated | Buy | $200 → $205 | 2025-08-28 |
| Citigroup | Reiterated | Buy | $190 → $210 | 2025-08-28 |
| KeyBanc Capital Markets | Reiterated | Overweight | $215 → $230 | 2025-08-28 |
| Rosenblatt | Reiterated | Buy | $200 → $215 | 2025-08-28 |
| Truist | Reiterated | Buy | $210 → $228 | 2025-08-28 |
| JP Morgan | Reiterated | Overweight | $170 → $215 | 2025-08-28 |
| Morgan Stanley | Reiterated | Overweight | $206 → $210 | 2025-08-28 |
| Bernstein | Reiterated | Outperform | $185 → $225 | 2025-08-28 |
| DA Davidson | Reiterated | Neutral | $135 → $195 | 2025-08-28 |
| Wolfe Research | Reiterated | Outperform | $220 → $230 | 2025-08-28 |
| Oppenheimer | Reiterated | Outperform | $200 → $225 | 2025-08-28 |
| Evercore ISI | Reiterated | Outperform | $190 → $214 | 2025-08-22 |
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|
| November 2025 | 10 | 49 | 4 | 1 | 0 |
| October 2025 | 10 | 49 | 4 | 1 | 0 |
| September 2025 | 10 | 48 | 4 | 1 | 0 |
| August 2025 | 10 | 47 | 6 | 1 | 0 |
The majority of institutional investors have issued a "Buy" rating for NVDA, and analyst sentiment aligns closely, with very few "Sell" recommendations. This suggests a broadly favorable outlook for the stock's performance.
